Developed States Retain Core Attractiveness, Emerging Markets Driving Future Growth

Evaluating the attractiveness of a pharmaceutical market as a potential investment opportunity requires broad-based awareness of a country's business environment. Industry-specific regulations for intellectual property, pricing and market access, demographics and epidemiology and political and economic stability are key considerations for drugmakers. However, raw market potential remains the prime indicator for companies strategising their market positioning. Here BMI assesses the most attractive markets globally in terms of three core indicators: market size; per-capita spending; and projected

To read the full article, please choose one of the following options: